Triple Vasopeptidase Inhibition Normalizes Blood Pressure in Conscious, Unrestrained, and Spontaneously Hypertensive Rats

The blood pressure-lowering effect of this triple VPI was superior to that of the other VPI in this preclinical rat model of hypertension. Further experiments are needed to assess triple VPI to other combinations in other models with regard to efficacy and angioedema. Only then it may constitute a first-in-class approach for the treatment of hypertension and other cardiovascular disorders.